Trial Profile
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUMINOSITY
- Sponsors AbbVie; AbbVie Germany
- 18 Jan 2024 Planned End Date changed from 24 Sep 2025 to 6 Oct 2025.
- 18 Jan 2024 Planned primary completion date changed from 24 Sep 2025 to 6 Oct 2025.
- 03 Dec 2023 As per Eudra the status of the trial is- trial now transitioned in Ireland. Hence, retained the status of the trial as per the other source.